Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMXV94M)

Drug Name
Inclacumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Sickle-cell disorder 3A51 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMXV94M

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
P-selectin (SELP) TTE5VG0 LYAM3_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
P-selectin (SELP) DTT SELP 7.304 7.427 7.315 7.849
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Sickle-cell disorder
ICD Disease Classification 3A51
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
P-selectin (SELP) DTT SELP 1.72E-04 1.23 0.86
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05348915) An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial. U.S.National Institutes of Health.
2 Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics. Expert Opin Biol Ther. 2022 Nov;22(11):1417-1428.